{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    6,
    16,
    29,
    55,
    69
  ],
  "modelUsed": "claude-opus-4-5",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "2",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "This non-substantial amendment was prepared to correct a typographical error in the schedule of activities. The PK sampling at 16 h postdose is not included in the schedule of activities, although the corresponding ECG measurement is included in the schedule of activities. The 16 h postdose blood sampling is present in Table 1 (Time Deviations from PK sampling times, Section 8.4.1) and is also consistently displayed in the ICF. Additionally, in Section 7.1 there was a harmonization with the preexisting next sentence. It was clarified, that if study intervention is permanently discontinued, the participant will remain in the study to be evaluated for safety assessments.",
        "effectiveDate": "2022-10-24",
        "reasonIds": [
          "ar_1_1"
        ],
        "previousVersion": "1.0",
        "newVersion": "2.0"
      },
      {
        "id": "amend_2",
        "number": "3",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "This non-substantial protocol amendment was prepared to allow rescreening of participants that were not previously enrolled in the study due to personal or logistical reasons or due to minor deviations that were not considered clinically relevant. Additional, wording of inclusion criteria was changed to have more flexibility regarding ratio of sexes.",
        "effectiveDate": "2022-12-01",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "2.0",
        "newVersion": "3.0"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "Germany",
        "instanceType": "Country",
        "code": "DE"
      },
      {
        "id": "country_2",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      },
      {
        "id": "country_3",
        "name": "Canada",
        "instanceType": "Country",
        "code": "CA"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 3,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3"
      ],
      "regions": [
        "Europe",
        "North America"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "2",
        "effectiveDate": "2022-10-24",
        "summary": "This non-substantial amendment was prepared to correct a typographical error in the schedule of activities. The PK sampling at 16 h postdose is not included in the schedule of activities, although the corresponding ECG measurement is included in the schedule of activities. The 16 h postdose blood sampling is present in Table 1 (Time Deviations from PK sampling times, Section 8.4.1) and is also consistently displayed in the ICF. Additionally, in Section 7.1 there was a harmonization with the preexisting next sentence. It was clarified, that if study intervention is permanently discontinued, the participant will remain in the study to be evaluated for safety assessments.",
        "previousVersion": "1.0",
        "newVersion": "2.0",
        "reasons": [
          "Administrative"
        ]
      },
      {
        "number": "3",
        "effectiveDate": "2022-12-01",
        "summary": "This non-substantial protocol amendment was prepared to allow rescreening of participants that were not previously enrolled in the study due to personal or logistical reasons or due to minor deviations that were not considered clinically relevant. Additional, wording of inclusion criteria was changed to have more flexibility regarding ratio of sexes.",
        "previousVersion": "2.0",
        "newVersion": "3.0",
        "reasons": [
          "Operational",
          "Administrative"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "Germany",
          "code": "DE"
        },
        {
          "name": "United States",
          "code": "US"
        },
        {
          "name": "Canada",
          "code": "CA"
        }
      ],
      "regions": [
        "Europe",
        "North America"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}